Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TATIN
2018-004798-29Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib and crizotinib in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoint: Percentage of patients with ctDNA-detected resistant clone before radiological progression. Started Jul 2019; status: completed.
02
Drugs
osimertinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-004798-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004798-29.